Depression During Pregnancy and Postpartum

Current Psychiatry Reports

Volumn 18, Issue 3, 2016, Pages 1-9

  Becker, Madeleine ^a   Weinberger, Tal ^a   Chandy, Ann ^a   Schmukler, Sarah ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Antidepressants; Depression; Lactation; Postpartum depression; Pregnancy

Indexed keywords

AMFEBUTAMONE; DESVENLAFAXINE; DULOXETINE; MIRTAZAPINE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TRAZODONE; VENLAFAXINE; ANTIDEPRESSANT AGENT;

ADAPTATION SYNDROME; AUTISM; BREAST FEEDING; DRUG LABELING; FEMALE; HUMAN; LOW BIRTH WEIGHT; MATERNAL BEHAVIOR; MOTHER CHILD RELATION; PERINATAL DEPRESSION; PREMATURE LABOR; PRENATAL EXPOSURE; PUERPERAL DEPRESSION; PULMONARY HYPERTENSION; REVIEW; RISK ASSESSMENT; TERATOGENESIS; TREATMENT INDICATION; DEPRESSION; DEPRESSION, POSTPARTUM; DEPRESSIVE DISORDER; PREGNANCY; PREGNANCY COMPLICATIONS; PSYCHOLOGY; PUERPERIUM;

ANTIDEPRESSIVE AGENTS; BREAST FEEDING; DEPRESSION; DEPRESSION, POSTPARTUM; DEPRESSIVE DISORDER; FEMALE; HUMANS; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84958250441     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-016-0664-7     Document Type: Review

References (116)

1. Committee on Obstetric Practice. The American College of Obstetricians and Gynecologists Committee Opinion no. 630. Screening for perinatal depression. Obstet Gynecol. 2015;125(5):1268–71.
2. ACOG Committee. Clinical Management Guidelines for Obstetrician–Gynecologists: use of psychiatric medications during pregnancy and lactation. ACOG Practice Bulletin No. 92. Obstet Gynecol. 2008;111(4):1001–20.
3. Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry. 2009;31(5):403–13.
4. Wisner KL, Sit DK, McShea MC, Rizzo DM, Zoretich RA, Hughes CL, et al. Onset timing, thoughts of self-harm, and diagnoses in postpartum women with screen-positive depression findings. JAMA Psychiatry. 2013;70(5):490–8. doi:10.1001/jamapsychiatry.2013.87.
5. Lindahl V, Pearson JL, Colpe L. Prevalence of suicidality during pregnancy and the postpartum. Arch Womens Ment Health. 2005;8(2):77–87.
6. Raisanen S, Lehto SM, et al. Risk factors for perinatal outcomes of major depression during pregnancy: a population-based analysis during 2002-2010 in Finland. BMJ Open. 2014;4(11):e004883.
7. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy and in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295(5):499–507.
8. Szegda K, Markenson G, Bertone-Johnson ER, Chasan-Taber L. Depression during pregnancy: a risk factor for adverse neonatal outcomes? A critical review of the literature. J Matern Fetal Neonatal Med. 2014;27(9):960–7.
9. Grigoriadis S, VonderPorten EH, Mamisahvili L, et al. The impact of maternal depression during pregnancy on perinatal outcomes: a systematic review and meta-analysis. J Clin Psychiatry. 2013;74(4):e321–41.
10. Ciesielski TH, Marsit CJ, Williams SM. Maternal psychiatric disease and epigenetic evidence suggest a common biology for poor fetal growth. BMC Pregnancy Childbirth. 2015;15:192. doi:10.1186/s12884-015-0627-8.
11. Davalos DB, Yadon CA, Tregellas HC. Untreated prenatal maternal depression and the potential risks to offspring: a review. Arch Womens Ment Health. 2012;15(1):1–14. doi:10.1007/s00737-011-0251-1.
12. Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry. 2010;67(10):1012–24.
13. Iliadis SI, Comasco E, Sylvén S, Hellgren C, Sundström Poromaa I, Skalkidou A. Prenatal and postpartum evening salivary cortisol levels in association with peripartum depressive symptoms. PLoS One. 2015;10(8):e0135471. doi:10.1371/journal.pone.0135471.eCollection2015.
14. Federenko IS, Wadhwa PD. Women’s mental health during pregnancy influences fetal and infant developmental and health outcomes. CNS Spectr. 2004;9(3):198–206.
15. Oberlander TF, Weinberg J, Papsdorf M, Grunau R, Misri S, Devlin AM. Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses. Epigenetics. 2008;3:97–106.
16. Wisner KL, Sit DK, Hanusa BH, Moses-Kolko EL, Bogen DL, Hunker DF, et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry. 2009;166(5):557–66. doi:10.1176/appi.ajp.2008.08081170.
17. Pearson RM, Melotti R, Heron J, Joinson C, Stein A, Ramchandani PG, et al. Disruption to the development of maternal responsiveness? The impact of prenatal depression on mother-infant interactions. Infant Behav Dev. 2012;35(4):613–26. doi:10.1016/j.infbeh.2012.07.020.
18. Robertson E, Grace S, Wallington T, et al. Antenatal risk factors for postpartum depression: a synthesis of recent literature. Gen Hosp Psychiatry. 2004;26:289–95.
19. Beck CT. Predictors of postpartum depression: an update. Nurs Res. 2001;50(5):275–85.
20. Gaillard A, Le Strat Y, Mandelbrot L, et al. Predictors of postpartum depression: prospective study of 264 women followed during pregnancy and postpartum. Psychiatry Res. 2014;215(2):341–6.
21. Kimmel M, Hess E, Roy PS. Family history, not lack of medication use, is associated with the development of postpartum depression in a high-risk sample. Arch Womens Ment Health. 2015;18:113–21.
22. Bloch M, Rotenberg N, Koren D, Klein E. Risk factors associated with the development of postpartum mood disorders. J Affect Disord. 2005;88(1):9–18.
23. Davanzo R, Copertino M, DeCunto A, et al. Antidepressant drugs and breastfeeding: a review of the literature. Breastfeed Med. 2011;6(2):89–98.
24. Dubber S, Reck C, Müller M, Gawlik S. Postpartum bonding: the role of perinatal depression, anxiety and maternal-fetal bonding during pregnancy. Arch Womens Ment Health. 2015;18(2):187–95. doi:10.1007/s00737-014-0445-4.
25. McLearn KT, Minkovitz CS, Strobino DM, Marks E, Hou W. Maternal depressive symptoms at 2 to 4 months post partum and early parenting practices. Arch Pediatr Adolesc Med. 2006;160(3):279–84.
26. Paulson JF, Dauber S, Leiferman JA. Individual and combined effects of postpartum depression in mothers and fathers on parenting behavior. Pediatrics. 2006;118(2):659–68.
27. Dias CC, Figueiredo B. Breastfeeding and depression: a systematic review of the literature. J Affect Disord. 2015;171:142–54. doi:10.1016/j.jad.2014.09.022.
28. Hatton DC, Harrison–Hohner J, Coste S, et al. Symptoms of postpartum depression and breastfeeding. J Hum Lac. 2005;21(44):444–9.
29. Feldman R, Granat A, Pariente C, et al. Maternal depression and anxiety across the postpartum year and infant social engagement, fear regulation, and stress reactivity. J Am Acad Child Adolesc Psychiatry. 2009;48(9):919–27.
30. Grace SL, Evindar A, Stewart DE. The effect of postpartum depression on child cognitive development and behavior: a review and critical analysis of the literature. Arch Women s Mental Health. 2003;6:263–74.
31. Pilowsky DJ, Wickramaratne PJ, Rush AJ, Hughes CW, Garber J, Malloy E, et al. Children of currently depressed mothers: a STAR*D ancillary study. J Clin Psychiatry. 2006;67(1):126–36.
32. Biederman J, Faraone SV, Hirshfel-Becker DR, Friedman D, Robin JA, Rosenbaum JF. Patterns of psychopathology and dysfunction in high-risk children of parents with panic disorder and major depression. Am J Psychiatry. 2001;158(1):59–7.
33. Berle JO, Spigset O. Antidepressant use during breastfeeding. Curr Womens Health Rev. 2011;7:28–34.
34. Fihrer I, McMahon CA, Taylor AJ. The impact of postnatal and concurrent maternal depression on child behavior during the early school years. J Affect Disord. 2009;119:116–23.
35. Werner E, Miller M, Osborne LM, Kuzava S, Monk C. Preventing postpartum depression: review and recommendations. Arch Womens Ment Health. 2015;18(1):41–60.
36. Sokol LE, Epperson CN, Barber JP. Preventing postpartum depression: a meta-analytic review. Clin Psychol Rev. 2013;33(8):1205–17.
37. USPTF. Final recommendation statement; depression in adults: screening. J Am Med Assoc. 2016;315(4):380–7
38. Byatt N, Deligiannidis KM, Freeman MP. Antidepressant use in pregnancy: a critical review focused on risks and controversies. Acta Psychiatr Scand. 2012:1–21. This is a large critical, comprehensive review examining multiple outcomes on teratogenicity, postnatal adaptation syndrome, and persistent pulmonary hypertension.
39. Suri R, Lin AS, et al. Acute and long-term behavioral outcomes of infants and children exposed in utero to either maternal depression or antidepressants: a review of the literature. J Clin Psychiatr. 2014;75(10):e1142–52.
40. Grigoriadis S. The effects of antidepressant medications on mothers and babies. J Popul Ther Clin Pharmacol. 2014;21(3):e533–41.
41. Drug labelling and pregnancy. Lancet. 2014 Dec 13;384(9960):2084. doi: 10.1016/S0140-6736(14)62356-4.
42. Ramoz LL, Patel Shori NM. Recent changes in pregnancy and lactation labeling: retirement of risk categories. Pharmacotherapy. 2014;34(4):389–95.
43. Food and Drug Administration, HHS. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Final rule. Fed Regist. 2014;79(233).
44. Louik C, Lin A, Werler M, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 2007;356(26):2675–83.
45. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systemic review and meta-analysis of the best evidence. J Clin Psychiatry. 2013;74(4):e293–308.
46. Kallen BA, Otterblad OP. Maternal use of selective serotonin-reuptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol. 2007;79(4):301–8.
47. Greene MF. Teratogenicity of SSRIs—serious concern or much ado about little? N Engl J Med. 2007;356:2732.
48. Yonkers KA, Blackwell KA, Glover J, Forray A. Antidepressant use in pregnant and postpartum women. Annu Rev Clinc Psychol. 2014;10:369–92.
49. Furu K, Kieler H, Haglund B, et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ. 2015;350:1798. 1-9.
50. Alwan S, Reefhuis J, Rasmussen SA, for National Birth Defects Prevention Study, et al. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med. 2007;356(26):2684–92.
51. Kendall-Tackett K, Hale TW. The use of antidepressants in pregnant and breastfeeding women: a review of recent studies. J Hum Lact. 2010;26(2):187–95.
52. Wurst KE, Poole C, Ephross SA, et al. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol. 2010;88(3):159–70.
53. Bakker MK, Kerstjens-Fredierikse WS, Buys CH, et al. First trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol. 2010;88(2):94–100.
54. Cole JA, Ephross SA, Cosmatos IS, et al. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf. 2007;16(10):1075–85.
55. Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med. 2010;40(10):1723–33.
56. Tuccori M. Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressant sure pregnancy: a review. Clin Ther. 2009;31:1426–53.
57. Einarson A, Pistelli A, DeSantis M, et al. Evaluation of the risk of congenital cardiovascular defects associated with the use of paroxetine during pregnancy. Am J Psychiatry. 2008;165(6):749–52.
58. Davis RL, Rubanowice D, McPhillips H, et al. Risk of congenital malformations and perinatal events among infants exposed to antidepressant medication during pregnancy. Pharmacoepidemiol Drug Saf. 2007;16(10):186–94.
59. Huybrechts KF, Palmesten K, Avorn J, et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014;370(25):2397–407. This was a large cohort study with 949,504 pregnant women comparing those who took antidepressants to those who did not, which found no substantial increase in the risk of cardiac malformations attributable to antidepressant use during the first trimester.
60. Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract. 2009;15(3):183–92.
61. Gentile S. Early pregnancy exposure to selective serotonin reuptake inhibitors, risks of major structural malformations, and hypothesized teratogenic mechanisms. Expert Opin Drug Metab Toxicol. 2015;1:1–13.
62. Huybrechts KF, Snghani RS, Avorn J, Urato AC. Preterm birth and antidepressant medication use during pregnancy: a systematic review and meta-analysis. PLoS One. 2014;9(3):e92778.
63. Oberlander TF, Warburton W, Misri S, et al. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. Br J Psychiatry. 2008;192:338–43.
64. Suri R, Alshuler L, Hellemann G, Burt VK, Aquino A, Mintz J. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatr. 2007;164(8):1206–13.
65. Ross LE, Grigoriadis S, Mamisashvili L, VonderPorten EH, Roerecke M, Rehm J, et al. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry. 2013;70:436–43. A review article looking at selected outcomes after exposure to antidepressant medications; this study showed that there was no association between antidepressant exposures. It also showed that there was an association with low birth weight, but compared to depressed moms without exposure, this was no longer a significant association. There have been adverse outcomes associated with both antidepressant exposure and depression.
66. Huang H, Coleman S, Bridge JA, Yonkers K, Katon W. A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight. Gen Hosp Psychiatry. 2014;36(1):13–8.
67. Sahingoz M, Yuksel G, Karsidag C, Uguz F, Sonmez EO, Annagur BB, et al. Birth weight and preterm birth in babies of pregnant women with major depression in relation to treatment with antidepressants. J Clin Psychopharmacol. 2014;34(2):226–9.
68. Rai D, Lee BK, Dalman C, Golding J, Lewis G, Manusson C. Parental depression, maternal antidepressant use during pregnancy, and the risk of autism spectrum disorders: population based case-control study. BMJ. 2013;346:f2059.
69. El Marroun H, Whilte T, Verhulst FC, Tiemeier H. Maternal use of antidepressant or anxiolytic medication during pregnancy and childhood neurodevelopmental outcomes: a systematic review. Eur Child Adolesc Psychiatry. 2014;23(10):973–92.
70. Harrington RA, Lee LC, Crum RM, Zimmerman AW, Hertz-Picciotto I. Prenatal SSRI use and offspring with autism spectrum disorder or developmental delay. Pediatrics. 2014;133(5):e1241–8.
71. Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry. 2011;68(11):1104–12.
72. Sorensen MJ, Gronborg TK, Christensen J, Parner ET, Vestergaard M, Schendel D, et al. Antidepressant exposure in pregnancy and risk of autism spectrum disorders. Clin Epidemiol. 2013;5:449–59.
73. Kallen Bm KOlausson PO. Maternal use of selective serotonin reuptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidmiol Drug Saf. 2008;17:801–6.
74. Huybrecs KF, Bateman BT, Palmsten K, et al. Antidepressant use late in pregnancy and the risk of persistent pulmonary hypertension of the newborn. JAMA. 2015;313(21):2142–51.
75. Kieler H, Artama M, Anders Engeland A, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 2012; 344. doi: 10.1136/bmj.d8012 (Published 12 January 2012) Cite this as: BMJ 2012;344:d8012
76. Chambers CD et al. Selective serotonin reuptake inhibitors and the risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354:579–87.
77. Eddahibi S, Raffestin B, Hamon M, Adnot S. Is the serotonin transporter involved in the pathogenesis of pulmonary hypertension? J Lab Clin Med. 2002;139:194–201.
78. Andrade SE, McPhillips H, Loren D, et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf. 2009;18:246–52.
79. Administration USFAD. FDA drug safety communication: selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and reports of a rare heart and lung condition in newborn babies. 12/4/11 ed2011.
80. Grigoriadis S, Vonderporten EH, Mamisashvili L, Tomlinson G, Dennis CL, Koren G, et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ. 2014;14:348.
81. Byatt N, Freeman MP. Exposure to selective serotonin reuptake inhibitors in late pregnancy increases the risk of persistent pulmonary hypertension of the newborn, but the absolute risk is low. Evid Based Nurs. 2015;18(1):15–6.
82. Chambers CD, Johnson KA, Dick LM, Feliz RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335(14):1010–5.
83. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005;293:2372–83.
84. Lennestal R, Kallen B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol. 2007;27:607–13.
85. Hibbard JU, Wilkins I, Sun L, et al. Respiratory morbidity in late preterm births. JAMA. 2010;304:419–25.
86. Byatt N et al. Antidepressant use in pregnancy: a critical review focused on risks and controversies. Acta Psychiatr Scand. 2013;127:94–114.
87. Einarson A, Bonari L, Voyer-Lavigne S, Addis A, Matsui D, Johnson Y, et al. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Canadian Journal of Psychiatry (Revue Canadienne de Psychiatrie). 2003;48(2):106–10.
88. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective studies. Pharmacoepidemiol Drug Saf. 2005;14(12):823–7.
89. Winterfeld U et al. Pregnancy outcome following maternal exposure to mirtazapine: a multicenter, prospective study. J Clin Psychopharmacol. 2015;35(3):250–9.
90. Djulus J et al. Exposure to mirtazapine during pregnancy: a prospective and comparative study of birth outcomes. J Clin Psych. 2006;67(8):1280–4.
91. GlaxoSmithKline. The Bupropion Pregnancy Registry final report. (2008): http://pregnnacy-registry.gsk.com/documents/bup_report_final-2008.pdf.
92. Alwan S, Reefhuis J, Botto LD, et al. Maternal use of bupropion and risk for congenital heart defects. Am J Obstet Gynecol. 2010;203(1):52.e1–6.
93. Chun-Fai-Chan B, Koren G, et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol. 2005;192:932–6.
94. Howard LM, Molyneux E, Dennis CL, Tamsen R, Stein A, Milgrom J. Non-psychotic mental disorders in the perinatal period. Perinatal Mental Health The Lancet. 2014;384(9956):15–21.
95. Anderson PO, Pochop SL, Manoguerra AS. Adverse drug reactions in breastfed infants: less than imagined. Clin Pediatr. 2003;42:325–40.
96. Eberhard-Gran M, Eskild A, Opjordsmoen S. Use of psychotropic medications in treating mood disorders during lactation: practical recommendations. CNS Drugs. 2006;20(3):187–98.
97. Lanza DiScalea T, Wisner KL. Antidepressant medication use during breastfeeding. Clin Obstet Gynecol. 2009;52(3):483–97.
98. Lester BM, Cucca J, Andreozzi L, et al. Possible association between fluoxetine hydrochloride and colic in an infant. J Am Acad Child Adolesc Psychiatry. 1993;32:1253–5.
99. Kristensen JH, Ilett KF, Hackett LP, Yapp P, Paech M, Begg EJ. Distribution and excretion of fluoxetine and norfluoxetine in human milk. Br J Clin Pharmacol. 1999;48(4):521–7.
100. Weissman AM, Levy BT, Hartz AJ, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry. 2004;161:1066–78.
101. Field T. Breastfeeding and antidepressants. Infant Behav Dev. 2008;31(3):481–7.
102. Gentile S. Use of contemporary antidepressants during breastfeeding: a proposal for a specific safety index. Drug Saf. 2007;30(2):107–21.
103. Potts AL, Young KL, Carter BS, Shenai JP. Necrotizing enterocolitis associated with in utero and breast milk exposure to the selective serotonin reuptake inhibitor, escitalopram. J Perinatol. 2007;27:120–2.
104. Chad L, Pupco A, Bozzo P, Koren G. Update on antidepressant use during breastfeeding. Can Fam Physician. 2013;59:633–4.
105. Andrade C. The safety of duloxetine during pregnancy and lactation. J Clin Psychiatry. 2014;75(12):e1423–7.
106. Rampono J, Teoh S, Hackett LP et al. Estimation of desvenlafaxine transfer into milk and infant exposure during its use in lactating women with postnatal depression. Arch Womens Ment Health. 2011;14:49–53.
107. Baab SW, Peindl KS, Piontek CW, Wisner KL. Serum bupropion levels in 2 breastfeeding mother-infant pairs. J Clin Psychiatry. 2002;63(10):910–1.
108. Haas J, Kaplan C, Barenboim D, et al. Bupropion in breast milk: an exposure assessment for potential treatment to prevent post-partum tobacco use. Tob Control. 2004;13(1):52–6.
109. Chaudron LH, Schoenecker CJ. Bupropion and breastfeeding: a case of a possible infant seizure. J Clin Psychiatry. 2004;65(6):881–2.
110. Aichhorn W, Whitworth AB, Weiss U, Stuppaeck C. Letters to the editor: Mirtazapine and breastfeeding. Am J Psychiatry. 2004;161(12):2325.
111. Klier CM, Moussaheb N, Lee A, Zernig G. Letters to the editor: Mirtazapine and breastfeeding: maternal and infant plasma levels. Am J Psychiatry. 2007;164(2):348–9.
112. Kristensen JH, Ilett KF, Rampono J, et al. Transfer of the antidepressant mirtazapine into breast milk. Br J Clin Psychiatr. 2007;63(3):322–7.
113. Tonn P, Reuter SC, Hiemke C, Dahmen N. High mirtazapine plasma levels in infant after breast feeding: case report and review of the literature. J Clin Psychopharmacol. 2009;29(2):191–2.
114. Verbeeck RK, Ross SG, McKenna EA. Excretion of trazodone in breast milk. Br J Clin Pharmacol. 1986;22(3):367–70.
115. Orsolini L, Bellantuono C. Serotonin reuptake inhibitors and breastfeeding: a systemic review. Hum Psychopharmacol Clin Exp. 2015;30:4–20.
116. Burt VK, Suri R, Altshuler L, et al. The use of psychotropic medications during breastfeeding. Am J Psychiatry. 2001;158:1001–9.